The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate [0.03%]
ESMO关于COVID-19疫苗接种和癌症患者的呼吁：接种。监测。教育。
M C Garassino,M Vyas,E G E de Vries et al.
M C Garassino et al.
Combined small-cell lung carcinoma revealed to be an intratumoural metastasis by genetic analysis [0.03%]
遗传分析发现的肿瘤内转移性小细胞肺癌
K D Lach,M Sorin,C Huynh et al.
K D Lach et al.
Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study [0.03%]
来那替尼治疗内分泌治疗失败的乳腺癌患者疗效和安全性的系统评价和meta分析PEARL研究的经验教训
E Agostinetto,M Ignatiadis
E Agostinetto
Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry [0.03%]
加州大学医疗系统登记处关于前列腺癌男性患者雄激素剥夺治疗与SARS-CoV-2感染结果的研究发现
D H Kwon,R Vashisht,H T Borno et al.
D H Kwon et al.
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† [0.03%]
多发性骨髓瘤：诊断、治疗和随访的临床实践指南
M A Dimopoulos,P Moreau,E Terpos et al.
M A Dimopoulos et al.
W Yu,J Hurley,D Roberts et al.
W Yu et al.
Liquid biopsy in cancer has gained momentum in clinical research and is experiencing a boom for a variety of applications. There are significant efforts to utilize liquid biopsies in cancer for early detection and treatment stratification, ...
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆ [0.03%]
复发性小细胞肺癌二线使用纳武单抗：CheckMate 331
D R Spigel,D Vicente,T E Ciuleanu et al.
D R Spigel et al.
Background: Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously treated SCLC. ...
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study [0.03%]
伊布替尼联合白蛋白结合型紫杉醇和吉西他滨用于转移性胰腺导管腺癌一线治疗：III期RESOLVE研究
M Tempero,D-Y Oh,J Tabernero et al.
M Tempero et al.
Background: First-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumor activity through tumor microe...
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis [0.03%]
科罗拉avin研究：cobimetinib联合化疗，序贯或联用atezolizumab对比医生选择的化疗一线治疗三阴性乳腺癌患者的2期随机试验主要分析结果
A Brufsky,S B Kim,Ž Zvirbule et al.
A Brufsky et al.
Background: Resistance to standard chemotherapy in metastatic triple-negative breast cancer (mTNBC) is associated with upregulation of the mitogen-activated protein kinase (MAPK) pathway. Cobimetinib, an MAPK/extracellula...